Skip to main content

Hexarelin vs PDA

Both Hexarelin and PDA are used for recovery. Here's how their evidence, dosing, and regulatory status actually compare.

Hexarelin

Evidence B

Hexarelin (HEX)

The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.

View full Hexarelin profile →

PDA

Evidence C+

Pentadeca Arginate (PDA)

A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.

View full PDA profile →

Side-by-Side

AttributeHexarelinPDA
Evidence GradeBC+
FDA StatusNot FDA-approved — research compound (cardioprotective signals investigated)Not FDA-approved — newer compounded analog of BPC-157
Typical Dose100 mcg, 1–2 times daily (subcutaneous)200–500 mcg daily (subcutaneous)
Clinics Indexed4141
Categoriesgrowth-hormone, recoveryrecovery, anti-inflammatory

Key reported benefits — Hexarelin

  • Strongest GH spike of GHRPs
  • Cardioprotective signals
  • Recovery

Key reported benefits — PDA

  • Tissue repair
  • Anti-inflammation
  • Potentially better stability than BPC-157

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons